Fig 1: Forest plot showing meta-analytic results of the sensitivity analysis for the studies that compared ITLN1 levels in people with cancer and healthy individuals after excluding the outlying study by Shen and colleagues (46). Model-averaged data are presented as SMD and 95% HDI.
Fig 2: Forest plot showing meta-analytic results for the comparison of ITLN1 levels in cancer patients and healthy individuals. Data are presented as SMD and 95% HDI.
Fig 3: Posterior distribution of ITLN1 levels in healthy individuals with a BMI>25. The point represents the mean of the posterior distribution and the thick line represents the 95% HDI.
Fig 4: Forest plot showing meta-analytic results of the robustness check for the studies that compared ITLN1 levels in people with urological cancer and healthy individuals Three studies (Uyeturk et al. (50); Frczkowski et al. (51); Borowski and Seminska et al. (52)) did not include a control group and the mean ITLN1 of healthy individuals (234 ± 21 ng/ml) was used as a reference point in these instances. Model-averaged data are presented as SMD and 95% HDI.
Fig 5: Forest plot showing meta-analytic results for studies that compared ITLN1 levels in people with urological cancer and healthy individuals. Model-averaged data are presented as SMD and 95% HDI.
Supplier Page from Abcam for Human Omentin ELISA Kit (ITLN1)